Objective Human body tries to keep blood pressure as stable and constant as possible, so its instabilities are indicators of systemicproblems. Among 1 B people affected by hypertension, however, blood pressure monitoring is ineffective at least in 47% ofthem, leading to 9 M deaths/year globally. Current monitors for self blood pressure monitoring show main drawbacks: theyinterfere with daily activities, often lack of reliability and standards, and only allow to measure the blood pressureintermittently, so information on the blood pressure trend is not available. BP24 is a wearable medical device fornoninvasive, continuous and highly accurate blood pressure monitoring, specifically targeting patients with hypertension andinpatients. Vita Sentry’s proprietary core technology enables a unique approach that takes into account the vascular tone tocompute the value of BP, instead of simply estimating it from the measure of the blood flow. By detecting the diameter ofarteries and arterioles with an accuracy of 0.5 μm over a measurement range, BP24 is the unique wearable intended forhighly accurate -golden-standard comparable- BP monitoring. Therefore, not only it can be used by patients withhypertension, but in the future it will be used in patients undergoing surgeries – and the company’s efforts are directedtowards that objective. Vita Sentry’s technology is enabling: being vasodilation and vasoconstriction in a number ofphysiological processes, knowing the arteries and arteriole diameters will allow to measure the metabolic rate and the stresslevel of a person. While this is a long-term objective, going to the market with BP24 for self-monitoring of people withhypertension is the goal of the innovation project. During Phase 1 project the Company will assess the scale-upindustrialization plan, the trials needed to demonstrate the validity of the proposed solution and will evaluate a sound go-tomarketstrategy to ensure successful commercialization of the device. Fields of science medical and health scienceshealth scienceshealth care serviceseHealthnatural sciencescomputer and information sciencesinternetinternet of thingsmedical and health sciencesclinical medicinesurgerysocial scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesclinical medicinecardiologycardiovascular diseases Programme(s) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator VITA-SENTRY LTD Net EU contribution € 50 000,00 Address 17 MOTZKIN STR. 4246017 NETANYA Israel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
